Fragile X syndrome: Lessons learned from the most translated neurodevelopmental disorder in clinical trials

Research output: Contribution to journalReview article

Abstract

Fragile X syndrome (FXS) is the leading genetic cause of autism spectrum disorder (ASD) and inherited intellectual disability (ID) worldwide. Preclinical successes in understanding the biology of FXS have led to numerous translational attempts in human clinical trials of therapeutics that target the excitatory/inhibitory neural signaling imbalances thought to underlie FXS. Despite the preclinical success story, the negative results of the human clinical trials have been deemed to be at least in part disappointing by the field. In this commentary, we contend that such negative studies results in clinical trials may actually propel the FXS field forward by serving as important lessons for designing and implementing improved future clinical trials such that can objectively assess the full range of responses to new therapeutics.

Original languageEnglish (US)
Pages (from-to)7-8
Number of pages2
JournalTranslational Neuroscience
Volume8
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Fragile X Syndrome
Clinical Trials
Pervasive Child Development Disorders
Intellectual Disability

Keywords

  • Autism spectrum disorder
  • Clinical trial
  • Fragile X syndrome
  • Translational research

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Fragile X syndrome : Lessons learned from the most translated neurodevelopmental disorder in clinical trials. / Duy, Phan Q.; Budimirovic, Dejan B.

In: Translational Neuroscience, Vol. 8, No. 1, 2017, p. 7-8.

Research output: Contribution to journalReview article

Duy, Phan Q.; Budimirovic, Dejan B. / Fragile X syndrome : Lessons learned from the most translated neurodevelopmental disorder in clinical trials.

In: Translational Neuroscience, Vol. 8, No. 1, 2017, p. 7-8.

Research output: Contribution to journalReview article

@article{9a29f63c56454787bbcfaa6bb1c96222,
title = "Fragile X syndrome: Lessons learned from the most translated neurodevelopmental disorder in clinical trials",
abstract = "Fragile X syndrome (FXS) is the leading genetic cause of autism spectrum disorder (ASD) and inherited intellectual disability (ID) worldwide. Preclinical successes in understanding the biology of FXS have led to numerous translational attempts in human clinical trials of therapeutics that target the excitatory/inhibitory neural signaling imbalances thought to underlie FXS. Despite the preclinical success story, the negative results of the human clinical trials have been deemed to be at least in part disappointing by the field. In this commentary, we contend that such negative studies results in clinical trials may actually propel the FXS field forward by serving as important lessons for designing and implementing improved future clinical trials such that can objectively assess the full range of responses to new therapeutics.",
keywords = "Autism spectrum disorder, Clinical trial, Fragile X syndrome, Translational research",
author = "Duy, {Phan Q.} and Budimirovic, {Dejan B.}",
year = "2017",
doi = "10.1515/tnsci-2017-0002",
volume = "8",
pages = "7--8",
journal = "Translational Neuroscience",
issn = "2081-3856",
publisher = "de Gruyter",
number = "1",

}

TY - JOUR

T1 - Fragile X syndrome

T2 - Translational Neuroscience

AU - Duy,Phan Q.

AU - Budimirovic,Dejan B.

PY - 2017

Y1 - 2017

N2 - Fragile X syndrome (FXS) is the leading genetic cause of autism spectrum disorder (ASD) and inherited intellectual disability (ID) worldwide. Preclinical successes in understanding the biology of FXS have led to numerous translational attempts in human clinical trials of therapeutics that target the excitatory/inhibitory neural signaling imbalances thought to underlie FXS. Despite the preclinical success story, the negative results of the human clinical trials have been deemed to be at least in part disappointing by the field. In this commentary, we contend that such negative studies results in clinical trials may actually propel the FXS field forward by serving as important lessons for designing and implementing improved future clinical trials such that can objectively assess the full range of responses to new therapeutics.

AB - Fragile X syndrome (FXS) is the leading genetic cause of autism spectrum disorder (ASD) and inherited intellectual disability (ID) worldwide. Preclinical successes in understanding the biology of FXS have led to numerous translational attempts in human clinical trials of therapeutics that target the excitatory/inhibitory neural signaling imbalances thought to underlie FXS. Despite the preclinical success story, the negative results of the human clinical trials have been deemed to be at least in part disappointing by the field. In this commentary, we contend that such negative studies results in clinical trials may actually propel the FXS field forward by serving as important lessons for designing and implementing improved future clinical trials such that can objectively assess the full range of responses to new therapeutics.

KW - Autism spectrum disorder

KW - Clinical trial

KW - Fragile X syndrome

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=85015676658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015676658&partnerID=8YFLogxK

U2 - 10.1515/tnsci-2017-0002

DO - 10.1515/tnsci-2017-0002

M3 - Review article

VL - 8

SP - 7

EP - 8

JO - Translational Neuroscience

JF - Translational Neuroscience

SN - 2081-3856

IS - 1

ER -